GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyka Labs Ltd (BOM:500259) » Definitions » Equity-to-Asset

Lyka Labs (BOM:500259) Equity-to-Asset : 0.44 (As of Mar. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Lyka Labs Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Lyka Labs's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₹682 Mil. Lyka Labs's Total Assets for the quarter that ended in Mar. 2024 was ₹1,567 Mil. Therefore, Lyka Labs's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.44.

The historical rank and industry rank for Lyka Labs's Equity-to-Asset or its related term are showing as below:

BOM:500259' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.14   Med: 0.16   Max: 0.44
Current: 0.44

During the past 13 years, the highest Equity to Asset Ratio of Lyka Labs was 0.44. The lowest was -0.14. And the median was 0.16.

BOM:500259's Equity-to-Asset is ranked worse than
68.33% of 1560 companies
in the Biotechnology industry
Industry Median: 0.67 vs BOM:500259: 0.44

Lyka Labs Equity-to-Asset Historical Data

The historical data trend for Lyka Labs's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyka Labs Equity-to-Asset Chart

Lyka Labs Annual Data
Trend Jun14 Jun15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 -0.14 0.07 0.30 0.44

Lyka Labs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 - 0.45 - 0.44

Competitive Comparison of Lyka Labs's Equity-to-Asset

For the Biotechnology subindustry, Lyka Labs's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lyka Labs's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyka Labs's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Lyka Labs's Equity-to-Asset falls into.



Lyka Labs Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Lyka Labs's Equity to Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Equity to Asset (A: Mar. 2024 )=Total Stockholders Equity/Total Assets
=681.543/1567.243
=0.43

Lyka Labs's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=681.543/1567.243
=0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lyka Labs  (BOM:500259) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Lyka Labs Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Lyka Labs's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Lyka Labs (BOM:500259) Business Description

Traded in Other Exchanges
Address
30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment viz. pharmaceuticals. The Company has presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.

Lyka Labs (BOM:500259) Headlines

No Headlines